Abbott Laboratories (NYSE: ABT) Stock Competitors & Peer Comparison
See ABT's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ABT and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ABT | $112.47 | +0.79% | 194.6B | 21.58 | $5.21 | +2.21% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| SYK | $330.69 | +2.66% | 126.8B | 24.70 | $13.39 | +1.05% |
| MDT | $91.23 | +1.40% | 116.7B | 16.49 | $5.53 | +3.12% |
| BSX | $46.84 | +0.36% | 69.6B | 15.11 | $3.10 | N/A |
| EW | $90.21 | +0.29% | 51.9B | 33.41 | $2.70 | N/A |
| DXCM | $90.82 | +1.71% | 34.3B | 35.62 | $2.55 | N/A |
| GEHC | $71.72 | -1.05% | 32.4B | 15.73 | $4.56 | +0.19% |
| PHG | $26.72 | -0.74% | 26.1B | 15.26 | $1.75 | +3.71% |
| ZBH | $100.91 | +1.44% | 19.5B | 11.90 | $8.48 | +0.95% |
Stock Comparison
Boston Scientific Corporation (NYSE: BSX-PA)
ABT vs BSX-PA Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, ABT's ROE is +0.11%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, ABT is less volatile compared to BSX-PA. This indicates lower risk in terms of short-term price fluctuations for ABT.Check BSX-PA's competition here
Stryker Corporation (NYSE: SYK)
ABT vs SYK Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, SYK has a market cap of 126.8B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while SYK trades at $330.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas SYK's P/E ratio is 24.70. In terms of profitability, ABT's ROE is +0.11%, compared to SYK's ROE of +0.16%. Regarding short-term risk, ABT is less volatile compared to SYK. This indicates lower risk in terms of short-term price fluctuations for ABT.Check SYK's competition here
Medtronic plc (NYSE: MDT)
ABT vs MDT Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, MDT has a market cap of 116.7B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while MDT trades at $91.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas MDT's P/E ratio is 16.49. In terms of profitability, ABT's ROE is +0.11%, compared to MDT's ROE of +0.10%. Regarding short-term risk, ABT is less volatile compared to MDT. This indicates lower risk in terms of short-term price fluctuations for ABT.Check MDT's competition here
Boston Scientific Corporation (NYSE: BSX)
ABT vs BSX Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, BSX has a market cap of 69.6B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while BSX trades at $46.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas BSX's P/E ratio is 15.11. In terms of profitability, ABT's ROE is +0.11%, compared to BSX's ROE of +0.15%. Regarding short-term risk, ABT is less volatile compared to BSX. This indicates lower risk in terms of short-term price fluctuations for ABT.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
ABT vs EW Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, EW has a market cap of 51.9B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while EW trades at $90.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas EW's P/E ratio is 33.41. In terms of profitability, ABT's ROE is +0.11%, compared to EW's ROE of +0.10%. Regarding short-term risk, ABT is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for ABT.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
ABT vs DXCM Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, DXCM has a market cap of 34.3B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while DXCM trades at $90.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas DXCM's P/E ratio is 35.62. In terms of profitability, ABT's ROE is +0.11%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, ABT is less volatile compared to DXCM. This indicates lower risk in terms of short-term price fluctuations for ABT.Check DXCM's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
ABT vs GEHC Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, GEHC has a market cap of 32.4B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while GEHC trades at $71.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas GEHC's P/E ratio is 15.73. In terms of profitability, ABT's ROE is +0.11%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, ABT is less volatile compared to GEHC. This indicates lower risk in terms of short-term price fluctuations for ABT.Check GEHC's competition here
Koninklijke Philips N.V. (NYSE: PHG)
ABT vs PHG Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, PHG has a market cap of 26.1B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while PHG trades at $26.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas PHG's P/E ratio is 15.26. In terms of profitability, ABT's ROE is +0.11%, compared to PHG's ROE of +0.10%. Regarding short-term risk, ABT is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for ABT.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
ABT vs ZBH Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, ZBH has a market cap of 19.5B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while ZBH trades at $100.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas ZBH's P/E ratio is 11.90. In terms of profitability, ABT's ROE is +0.11%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, ABT is less volatile compared to ZBH. This indicates lower risk in terms of short-term price fluctuations for ABT.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
ABT vs ABMD Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas ABMD's P/E ratio is 65.36. In terms of profitability, ABT's ROE is +0.11%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, ABT is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for ABT.Check ABMD's competition here
Penumbra, Inc. (NYSE: PEN)
ABT vs PEN Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, PEN has a market cap of 12.7B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while PEN trades at $321.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas PEN's P/E ratio is 84.03. In terms of profitability, ABT's ROE is +0.11%, compared to PEN's ROE of +0.11%. Regarding short-term risk, ABT is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for ABT.Check PEN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
ABT vs SWAV Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas SWAV's P/E ratio is 78.76. In terms of profitability, ABT's ROE is +0.11%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, ABT is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for ABT.Check SWAV's competition here
Smith & Nephew plc (NYSE: SNN)
ABT vs SNN Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, SNN has a market cap of 12.2B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while SNN trades at $28.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas SNN's P/E ratio is 13.64. In terms of profitability, ABT's ROE is +0.11%, compared to SNN's ROE of +0.12%. Regarding short-term risk, ABT is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for ABT.Check SNN's competition here
Align Technology, Inc. (NASDAQ: ALGN)
ABT vs ALGN Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, ALGN has a market cap of 11.3B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while ALGN trades at $157.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas ALGN's P/E ratio is 14.36. In terms of profitability, ABT's ROE is +0.11%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, ABT is less volatile compared to ALGN. This indicates lower risk in terms of short-term price fluctuations for ABT.Check ALGN's competition here
Globus Medical, Inc. (NYSE: GMED)
ABT vs GMED Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, GMED has a market cap of 11.2B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while GMED trades at $82.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas GMED's P/E ratio is 18.69. In terms of profitability, ABT's ROE is +0.11%, compared to GMED's ROE of +0.12%. Regarding short-term risk, ABT is less volatile compared to GMED. This indicates lower risk in terms of short-term price fluctuations for ABT.Check GMED's competition here
Glaukos Corporation (NYSE: GKOS)
ABT vs GKOS Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, GKOS has a market cap of 10.6B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while GKOS trades at $179.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas GKOS's P/E ratio is -209.16. In terms of profitability, ABT's ROE is +0.11%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, ABT is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for ABT.Check GKOS's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
ABT vs BIO-B Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, BIO-B has a market cap of 10.6B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while BIO-B trades at $387.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas BIO-B's P/E ratio is -68.15. In terms of profitability, ABT's ROE is +0.11%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, ABT is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for ABT.Check BIO-B's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
ABT vs BIO Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, BIO has a market cap of 10.4B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while BIO trades at $387.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas BIO's P/E ratio is 41.79. In terms of profitability, ABT's ROE is +0.11%, compared to BIO's ROE of +0.03%. Regarding short-term risk, ABT is less volatile compared to BIO. This indicates lower risk in terms of short-term price fluctuations for ABT.Check BIO's competition here
Insulet Corp. (NASDAQ: PODD)
ABT vs PODD Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, PODD has a market cap of 10.1B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while PODD trades at $145.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas PODD's P/E ratio is 24.72. In terms of profitability, ABT's ROE is +0.11%, compared to PODD's ROE of +0.27%. Regarding short-term risk, ABT is less volatile compared to PODD. This indicates lower risk in terms of short-term price fluctuations for ABT.Check PODD's competition here
Masimo Corporation (NASDAQ: MASI)
ABT vs MASI Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas MASI's P/E ratio is 44.43. In terms of profitability, ABT's ROE is +0.11%, compared to MASI's ROE of +0.09%. Regarding short-term risk, ABT is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for ABT.Check MASI's competition here
Bruker Corporation (NASDAQ: BRKR)
ABT vs BRKR Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, BRKR has a market cap of 8.7B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while BRKR trades at $57.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas BRKR's P/E ratio is 28.68. In terms of profitability, ABT's ROE is +0.11%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, ABT is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for ABT.Check BRKR's competition here
Bruker Corporation (NASDAQ: BRKRP)
ABT vs BRKRP Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, BRKRP has a market cap of 8.5B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while BRKRP trades at $420.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas BRKRP's P/E ratio is 229.28. In terms of profitability, ABT's ROE is +0.11%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, ABT is less volatile compared to BRKRP. This indicates lower risk in terms of short-term price fluctuations for ABT.Check BRKRP's competition here
Haemonetics Corporation (NYSE: HAE)
ABT vs HAE Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, HAE has a market cap of 4.7B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while HAE trades at $103.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas HAE's P/E ratio is 20.74. In terms of profitability, ABT's ROE is +0.11%, compared to HAE's ROE of +0.11%. Regarding short-term risk, ABT is less volatile compared to HAE. This indicates lower risk in terms of short-term price fluctuations for ABT.Check HAE's competition here
Inari Medical, Inc. (NASDAQ: NARI)
ABT vs NARI Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas NARI's P/E ratio is -59.24. In terms of profitability, ABT's ROE is +0.11%, compared to NARI's ROE of -0.00%. Regarding short-term risk, ABT is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for ABT.Check NARI's competition here
LivaNova PLC (NASDAQ: LIVN)
ABT vs LIVN Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, LIVN has a market cap of 4.4B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while LIVN trades at $80.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas LIVN's P/E ratio is 19.08. In terms of profitability, ABT's ROE is +0.11%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, ABT is less volatile compared to LIVN. This indicates lower risk in terms of short-term price fluctuations for ABT.Check LIVN's competition here
Integer Holdings Corporation (NYSE: ITGR)
ABT vs ITGR Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while ITGR trades at $125.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas ITGR's P/E ratio is 19.73. In terms of profitability, ABT's ROE is +0.11%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, ABT is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for ABT.Check ITGR's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
ABT vs IRTC Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, IRTC has a market cap of 3.8B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while IRTC trades at $120.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas IRTC's P/E ratio is -270.53. In terms of profitability, ABT's ROE is +0.11%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, ABT is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for ABT.Check IRTC's competition here
Axonics, Inc. (NASDAQ: AXNX)
ABT vs AXNX Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas AXNX's P/E ratio is -709.80. In terms of profitability, ABT's ROE is +0.11%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, ABT is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for ABT.Check AXNX's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
ABT vs TMDX Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, TMDX has a market cap of 3.1B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while TMDX trades at $88.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas TMDX's P/E ratio is 44.89. In terms of profitability, ABT's ROE is +0.11%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, ABT is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for ABT.Check TMDX's competition here
AxoGen, Inc. (NASDAQ: AXGN)
ABT vs AXGN Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, AXGN has a market cap of 2.8B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while AXGN trades at $51.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas AXGN's P/E ratio is 135.45. In terms of profitability, ABT's ROE is +0.11%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, ABT is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for ABT.Check AXGN's competition here
Neogen Corporation (NASDAQ: NEOG)
ABT vs NEOG Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, NEOG has a market cap of 2.5B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while NEOG trades at $11.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas NEOG's P/E ratio is 41.64. In terms of profitability, ABT's ROE is +0.11%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, ABT is less volatile compared to NEOG. This indicates lower risk in terms of short-term price fluctuations for ABT.Check NEOG's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
ABT vs UFPT Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, UFPT has a market cap of 2.3B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while UFPT trades at $300.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas UFPT's P/E ratio is 30.65. In terms of profitability, ABT's ROE is +0.11%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, ABT is less volatile compared to UFPT. This indicates lower risk in terms of short-term price fluctuations for ABT.Check UFPT's competition here
Butterfly Network, Inc. (NYSE: BFLY)
ABT vs BFLY Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, BFLY has a market cap of 2.2B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while BFLY trades at $8.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas BFLY's P/E ratio is -35.12. In terms of profitability, ABT's ROE is +0.11%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, ABT is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for ABT.Check BFLY's competition here
NuVasive, Inc. (NASDAQ: NUVA)
ABT vs NUVA Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas NUVA's P/E ratio is 75.00. In terms of profitability, ABT's ROE is +0.11%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, ABT is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for ABT.Check NUVA's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
ABT vs ESTA Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, ESTA has a market cap of 2.1B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while ESTA trades at $70.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas ESTA's P/E ratio is -56.06. In terms of profitability, ABT's ROE is +0.11%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, ABT is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for ABT.Check ESTA's competition here
Novocure Ltd (NASDAQ: NVCR)
ABT vs NVCR Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, NVCR has a market cap of 2.1B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while NVCR trades at $17.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas NVCR's P/E ratio is -13.71. In terms of profitability, ABT's ROE is +0.11%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, ABT is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for ABT.Check NVCR's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
ABT vs INSP Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, INSP has a market cap of 1.8B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while INSP trades at $61.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas INSP's P/E ratio is 27.10. In terms of profitability, ABT's ROE is +0.11%, compared to INSP's ROE of +0.18%. Regarding short-term risk, ABT is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for ABT.Check INSP's competition here
CONMED Corporation (NYSE: CNMD)
ABT vs CNMD Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, CNMD has a market cap of 1.5B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while CNMD trades at $49.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas CNMD's P/E ratio is 11.00. In terms of profitability, ABT's ROE is +0.11%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, ABT is less volatile compared to CNMD. This indicates lower risk in terms of short-term price fluctuations for ABT.Check CNMD's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
ABT vs TNDM Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, TNDM has a market cap of 1.5B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while TNDM trades at $21.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas TNDM's P/E ratio is -23.04. In terms of profitability, ABT's ROE is +0.11%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, ABT is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for ABT.Check TNDM's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
ABT vs ATEC Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, ATEC has a market cap of 1.5B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while ATEC trades at $9.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas ATEC's P/E ratio is -157.33. In terms of profitability, ABT's ROE is +0.11%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, ABT is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for ABT.Check ATEC's competition here
Enovis Corporation (NYSE: ENOV)
ABT vs ENOV Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, ENOV has a market cap of 1.4B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while ENOV trades at $24.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas ENOV's P/E ratio is 7.13. In terms of profitability, ABT's ROE is +0.11%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, ABT is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for ABT.Check ENOV's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
ABT vs IART Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while IART trades at $16.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas IART's P/E ratio is 7.16. In terms of profitability, ABT's ROE is +0.11%, compared to IART's ROE of -0.01%. Regarding short-term risk, ABT is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for ABT.Check IART's competition here
Heska Corporation (NASDAQ: HSKA)
ABT vs HSKA Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas HSKA's P/E ratio is -62.49. In terms of profitability, ABT's ROE is +0.11%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, ABT is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for ABT.Check HSKA's competition here
Artivion, Inc. (NYSE: AORT)
ABT vs AORT Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, AORT has a market cap of 1.3B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while AORT trades at $26.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas AORT's P/E ratio is 44.57. In terms of profitability, ABT's ROE is +0.11%, compared to AORT's ROE of -0.01%. Regarding short-term risk, ABT is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for ABT.Check AORT's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
ABT vs PRCT Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, PRCT has a market cap of 1.2B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while PRCT trades at $20.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas PRCT's P/E ratio is -10.74. In terms of profitability, ABT's ROE is +0.11%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, ABT is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for ABT.Check PRCT's competition here
Avanos Medical, Inc. (NYSE: AVNS)
ABT vs AVNS Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas AVNS's P/E ratio is 27.77. In terms of profitability, ABT's ROE is +0.11%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, ABT is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for ABT.Check AVNS's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
ABT vs SILK Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas SILK's P/E ratio is -18.96. In terms of profitability, ABT's ROE is +0.11%, compared to SILK's ROE of -0.35%. Regarding short-term risk, ABT is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for ABT.Check SILK's competition here
IRadimed Corporation (NASDAQ: IRMD)
ABT vs IRMD Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while IRMD trades at $87.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas IRMD's P/E ratio is 43.75. In terms of profitability, ABT's ROE is +0.11%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, ABT is less volatile compared to IRMD. This indicates lower risk in terms of short-term price fluctuations for ABT.Check IRMD's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
ABT vs LMRI Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, LMRI has a market cap of 1.1B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while LMRI trades at $11.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas LMRI's P/E ratio is -22.39. In terms of profitability, ABT's ROE is +0.11%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, ABT is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for ABT.Check LMRI's competition here
Paragon 28, Inc. (NYSE: FNA)
ABT vs FNA Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas FNA's P/E ratio is -19.83. In terms of profitability, ABT's ROE is +0.11%, compared to FNA's ROE of -0.35%. Regarding short-term risk, ABT is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for ABT.Check FNA's competition here
Bioventus Inc. (NASDAQ: BVS)
ABT vs BVS Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, BVS has a market cap of 937.6M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while BVS trades at $13.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas BVS's P/E ratio is 18.21. In terms of profitability, ABT's ROE is +0.11%, compared to BVS's ROE of +0.28%. Regarding short-term risk, ABT is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for ABT.Check BVS's competition here
CeriBell, Inc. (NASDAQ: CBLL)
ABT vs CBLL Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, CBLL has a market cap of 900.4M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while CBLL trades at $23.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas CBLL's P/E ratio is -13.48. In terms of profitability, ABT's ROE is +0.11%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, ABT is less volatile compared to CBLL. This indicates lower risk in terms of short-term price fluctuations for ABT.Check CBLL's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
ABT vs BBNX Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, BBNX has a market cap of 887.2M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while BBNX trades at $19.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas BBNX's P/E ratio is -11.95. In terms of profitability, ABT's ROE is +0.11%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, ABT is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for ABT.Check BBNX's competition here
InMode Ltd. (NASDAQ: INMD)
ABT vs INMD Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, INMD has a market cap of 853.6M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while INMD trades at $14.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas INMD's P/E ratio is 10.31. In terms of profitability, ABT's ROE is +0.11%, compared to INMD's ROE of +0.12%. Regarding short-term risk, ABT is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for ABT.Check INMD's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
ABT vs SIBN Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, SIBN has a market cap of 852M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while SIBN trades at $19.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas SIBN's P/E ratio is -56.50. In terms of profitability, ABT's ROE is +0.11%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, ABT is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for ABT.Check SIBN's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
ABT vs AVR Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, AVR has a market cap of 849.8M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while AVR trades at $8.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas AVR's P/E ratio is -4.51. In terms of profitability, ABT's ROE is +0.11%, compared to AVR's ROE of -0.78%. Regarding short-term risk, ABT is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for ABT.Check AVR's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
ABT vs CSII Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas CSII's P/E ratio is -20.83. In terms of profitability, ABT's ROE is +0.11%, compared to CSII's ROE of -0.14%. Regarding short-term risk, ABT is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for ABT.Check CSII's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
ABT vs AHCO Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, AHCO has a market cap of 787.8M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while AHCO trades at $5.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas AHCO's P/E ratio is 11.82. In terms of profitability, ABT's ROE is +0.11%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, ABT is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for ABT.Check AHCO's competition here
Varex Imaging Corporation (NASDAQ: VREX)
ABT vs VREX Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, VREX has a market cap of 778.9M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while VREX trades at $18.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas VREX's P/E ratio is 19.47. In terms of profitability, ABT's ROE is +0.11%, compared to VREX's ROE of +0.05%. Regarding short-term risk, ABT is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for ABT.Check VREX's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
ABT vs SSII Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, SSII has a market cap of 696.5M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while SSII trades at $3.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas SSII's P/E ratio is -67.88. In terms of profitability, ABT's ROE is +0.11%, compared to SSII's ROE of -0.27%. Regarding short-term risk, ABT is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for ABT.Check SSII's competition here
Surmodics, Inc. (NASDAQ: SRDX)
ABT vs SRDX Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas SRDX's P/E ratio is -34.66. In terms of profitability, ABT's ROE is +0.11%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, ABT is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for ABT.Check SRDX's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
ABT vs CTKB Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, CTKB has a market cap of 604.4M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while CTKB trades at $4.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas CTKB's P/E ratio is -24.79. In terms of profitability, ABT's ROE is +0.11%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, ABT is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for ABT.Check CTKB's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
ABT vs KIDS Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, KIDS has a market cap of 599M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while KIDS trades at $23.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas KIDS's P/E ratio is -19.76. In terms of profitability, ABT's ROE is +0.11%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, ABT is less volatile compared to KIDS. This indicates lower risk in terms of short-term price fluctuations for ABT.Check KIDS's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
ABT vs APEN Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas APEN's P/E ratio is -9.43. In terms of profitability, ABT's ROE is +0.11%, compared to APEN's ROE of -0.85%. Regarding short-term risk, ABT is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for ABT.Check APEN's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
ABT vs DCTH Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, DCTH has a market cap of 564.1M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while DCTH trades at $16.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas DCTH's P/E ratio is 1634.00. In terms of profitability, ABT's ROE is +0.11%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, ABT is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for ABT.Check DCTH's competition here
ZimVie Inc. (NASDAQ: ZIMV)
ABT vs ZIMV Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, ABT's ROE is +0.11%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, ABT is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for ABT.Check ZIMV's competition here
Cerus Corporation (NASDAQ: CERS)
ABT vs CERS Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, CERS has a market cap of 534M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while CERS trades at $2.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas CERS's P/E ratio is -52.89. In terms of profitability, ABT's ROE is +0.11%, compared to CERS's ROE of -0.10%. Regarding short-term risk, ABT is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for ABT.Check CERS's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
ABT vs TCMD Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, TCMD has a market cap of 522.4M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while TCMD trades at $23.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas TCMD's P/E ratio is 21.44. In terms of profitability, ABT's ROE is +0.11%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, ABT is less volatile compared to TCMD. This indicates lower risk in terms of short-term price fluctuations for ABT.Check TCMD's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
ABT vs NPCE Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, NPCE has a market cap of 491.3M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while NPCE trades at $14.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas NPCE's P/E ratio is -25.28. In terms of profitability, ABT's ROE is +0.11%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, ABT is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for ABT.Check NPCE's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
ABT vs CLPT Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, CLPT has a market cap of 466.3M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while CLPT trades at $15.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas CLPT's P/E ratio is -13.18. In terms of profitability, ABT's ROE is +0.11%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, ABT is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for ABT.Check CLPT's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
ABT vs SGHT Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, SGHT has a market cap of 465.2M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while SGHT trades at $8.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas SGHT's P/E ratio is -15.27. In terms of profitability, ABT's ROE is +0.11%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, ABT is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for ABT.Check SGHT's competition here
Carlsmed, Inc. (NASDAQ: CARL)
ABT vs CARL Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, CARL has a market cap of 458.9M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while CARL trades at $16.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas CARL's P/E ratio is -11.80. In terms of profitability, ABT's ROE is +0.11%, compared to CARL's ROE of -0.38%. Regarding short-term risk, ABT is less volatile compared to CARL. This indicates lower risk in terms of short-term price fluctuations for ABT.Check CARL's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
ABT vs PACB Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, PACB has a market cap of 434.8M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while PACB trades at $1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas PACB's P/E ratio is -3.41. In terms of profitability, ABT's ROE is +0.11%, compared to PACB's ROE of -49.62%. Regarding short-term risk, ABT is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for ABT.Check PACB's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
ABT vs OFIX Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, OFIX has a market cap of 392.1M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while OFIX trades at $9.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas OFIX's P/E ratio is -6.32. In terms of profitability, ABT's ROE is +0.11%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, ABT is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for ABT.Check OFIX's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
ABT vs SENS Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, SENS has a market cap of 389.9M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while SENS trades at $9.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas SENS's P/E ratio is -4.18. In terms of profitability, ABT's ROE is +0.11%, compared to SENS's ROE of -1.66%. Regarding short-term risk, ABT is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for ABT.Check SENS's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
ABT vs CATX Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, CATX has a market cap of 353M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while CATX trades at $3.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas CATX's P/E ratio is -2.33. In terms of profitability, ABT's ROE is +0.11%, compared to CATX's ROE of -0.42%. Regarding short-term risk, ABT is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for ABT.Check CATX's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
ABT vs SMLR Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas SMLR's P/E ratio is 3.92. In terms of profitability, ABT's ROE is +0.11%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, ABT is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for ABT.Check SMLR's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
ABT vs TMCI Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, TMCI has a market cap of 301.7M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while TMCI trades at $4.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas TMCI's P/E ratio is -4.95. In terms of profitability, ABT's ROE is +0.11%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, ABT is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for ABT.Check TMCI's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
ABT vs TLSI Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, TLSI has a market cap of 297.4M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while TLSI trades at $4.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas TLSI's P/E ratio is -2.87. In terms of profitability, ABT's ROE is +0.11%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, ABT is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for ABT.Check TLSI's competition here
CapsoVision, Inc. (NASDAQ: CV)
ABT vs CV Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, CV has a market cap of 296.3M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while CV trades at $5.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas CV's P/E ratio is -2.37. In terms of profitability, ABT's ROE is +0.11%, compared to CV's ROE of -1.78%. Regarding short-term risk, ABT is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for ABT.Check CV's competition here
RxSight, Inc. (NASDAQ: RXST)
ABT vs RXST Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, RXST has a market cap of 291.8M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while RXST trades at $7.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas RXST's P/E ratio is -6.24. In terms of profitability, ABT's ROE is +0.11%, compared to RXST's ROE of -0.17%. Regarding short-term risk, ABT is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for ABT.Check RXST's competition here
Avita Medical Inc. (NASDAQ: RCEL)
ABT vs RCEL Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, RCEL has a market cap of 257.1M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while RCEL trades at $10.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas RCEL's P/E ratio is -7.19. In terms of profitability, ABT's ROE is +0.11%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, ABT is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for ABT.Check RCEL's competition here
Profound Medical Corp. (NASDAQ: PROF)
ABT vs PROF Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, PROF has a market cap of 248.9M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while PROF trades at $6.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas PROF's P/E ratio is -6.99. In terms of profitability, ABT's ROE is +0.11%, compared to PROF's ROE of -0.56%. Regarding short-term risk, ABT is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for ABT.Check PROF's competition here
Electromed, Inc. (AMEX: ELMD)
ABT vs ELMD Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, ELMD has a market cap of 245.3M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while ELMD trades at $29.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas ELMD's P/E ratio is 22.61. In terms of profitability, ABT's ROE is +0.11%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, ABT is less volatile compared to ELMD. This indicates lower risk in terms of short-term price fluctuations for ABT.Check ELMD's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
ABT vs MGRM Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas MGRM's P/E ratio is -12.00. In terms of profitability, ABT's ROE is +0.11%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, ABT is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for ABT.Check MGRM's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
ABT vs INFU Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, INFU has a market cap of 242.6M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while INFU trades at $12.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas INFU's P/E ratio is 29.32. In terms of profitability, ABT's ROE is +0.11%, compared to INFU's ROE of +0.15%. Regarding short-term risk, ABT is more volatile compared to INFU. This indicates higher risk in terms of short-term price fluctuations for ABT.Check INFU's competition here
Nevro Corp. (NYSE: NVRO)
ABT vs NVRO Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas NVRO's P/E ratio is -1.91. In terms of profitability, ABT's ROE is +0.11%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, ABT is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for ABT.Check NVRO's competition here
Neuronetics, Inc. (NASDAQ: STIM)
ABT vs STIM Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, STIM has a market cap of 204.6M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while STIM trades at $2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas STIM's P/E ratio is -6.68. In terms of profitability, ABT's ROE is +0.11%, compared to STIM's ROE of -1.51%. Regarding short-term risk, ABT is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for ABT.Check STIM's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
ABT vs BSGM Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas BSGM's P/E ratio is -5.81. In terms of profitability, ABT's ROE is +0.11%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, ABT is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for ABT.Check BSGM's competition here
Lucid Diagnostics Inc. (NASDAQ: LUCD)
ABT vs LUCD Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, LUCD has a market cap of 189.1M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while LUCD trades at $0.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas LUCD's P/E ratio is -2.68. In terms of profitability, ABT's ROE is +0.11%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, ABT is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for ABT.Check LUCD's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
ABT vs MDGS Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas MDGS's P/E ratio is -0.27. In terms of profitability, ABT's ROE is +0.11%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, ABT is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for ABT.Check MDGS's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
ABT vs QIPT Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas QIPT's P/E ratio is -15.87. In terms of profitability, ABT's ROE is +0.11%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, ABT is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for ABT.Check QIPT's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
ABT vs FOCL Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, FOCL has a market cap of 161.5M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while FOCL trades at $4.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas FOCL's P/E ratio is -4.17. In terms of profitability, ABT's ROE is +0.11%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, ABT is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for ABT.Check FOCL's competition here
Quantum-Si incorporated (NASDAQ: QSI)
ABT vs QSI Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, QSI has a market cap of 154.3M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while QSI trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas QSI's P/E ratio is -1.70. In terms of profitability, ABT's ROE is +0.11%, compared to QSI's ROE of -0.47%. Regarding short-term risk, ABT is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for ABT.Check QSI's competition here
Inogen, Inc. (NASDAQ: INGN)
ABT vs INGN Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, INGN has a market cap of 148.9M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while INGN trades at $5.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas INGN's P/E ratio is -6.04. In terms of profitability, ABT's ROE is +0.11%, compared to INGN's ROE of -0.13%. Regarding short-term risk, ABT is less volatile compared to INGN. This indicates lower risk in terms of short-term price fluctuations for ABT.Check INGN's competition here
Quanterix Corporation (NASDAQ: QTRX)
ABT vs QTRX Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, QTRX has a market cap of 124.4M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while QTRX trades at $2.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas QTRX's P/E ratio is -1.04. In terms of profitability, ABT's ROE is +0.11%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, ABT is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for ABT.Check QTRX's competition here
iCAD, Inc. (NASDAQ: ICAD)
ABT vs ICAD Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas ICAD's P/E ratio is -20.37. In terms of profitability, ABT's ROE is +0.11%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, ABT is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for ABT.Check ICAD's competition here
LENSAR Inc (NASDAQ: LNSR)
ABT vs LNSR Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, LNSR has a market cap of 101.9M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while LNSR trades at $8.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas LNSR's P/E ratio is 8.47. In terms of profitability, ABT's ROE is +0.11%, compared to LNSR's ROE of +103.80%. Regarding short-term risk, ABT is less volatile compared to LNSR. This indicates lower risk in terms of short-term price fluctuations for ABT.Check LNSR's competition here
Pulmonx Corporation (NASDAQ: LUNG)
ABT vs LUNG Comparison September 2026
Abbott Laboratories (NYSE: ABT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 194.6B. In comparison, LUNG has a market cap of 100.5M. Regarding current trading prices, ABT is priced at $112.47 on the NYSE, while LUNG trades at $2.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 21.58, whereas LUNG's P/E ratio is -2.05. In terms of profitability, ABT's ROE is +0.11%, compared to LUNG's ROE of -0.97%. Regarding short-term risk, ABT is less volatile compared to LUNG. This indicates lower risk in terms of short-term price fluctuations for ABT.Check LUNG's competition here